Labiotech.eu

News and Trends 20 Nov 2023

M&As: what’s up with the ADC buying spree?

Antibody drug conjugates (ADCs) have been much sought-after through investments of late, with big pharma eyeing these drugs developed by various biotechs, to eventually nab them. With yet another ADC being bought by Bristol Myers Squibb, and AbbVie’s proposed $10 billion deal to seize ImmunoGen’s oncology pipeline, are these drugs the golden ticket to targeted […]

November 20, 2023 - 7 minutesmins - By Roohi Mariam Peter

News and Trends 17 Nov 2023

With $700 million Q3 rise, U.K. biotech spearheads European recovery

The U.K.’s biotechnology landscape has witnessed an impressive surge in funding, clocking a robust £563 million ($700 million) in venture capital and public financings in the third quarter of 2023, according to Biotech Finance. This achievement marks a staggering 48% increase from the previous quarter and sets a formidable pace that is already on track […]

November 17, 2023 - 4 minutesmins - By Jules Adam

Podcast 17 Nov 2023

How can life-saving vaccines be more affordable?

Phenotypeca, a biotech business from Nottingham, UK, has been working with the Bill & Melinda Gates Foundation to produce albumin for low and middle-income countries (LMICs), offering a catalyst for making life-saving vaccines affordable globally. Global vaccine production faces several challenges. Limited availability and the high costs associated with recombinant albumin act as a barrier […]

November 17, 2023

In Depth 16 Nov 2023

uniQure: is the gene therapy pioneer en route to becoming a biotech rebuff?

Once thought to be a frontrunner in gene therapy, uniQure’s fame may no longer be coveted, as the biotech looks to reorganize by slashing its workforce, in an attempt to stay afloat. But how did things go awry for the company that was once in its prime in the DNA game? The Danish company, which […]

November 16, 2023 - 7 minutesmins - By Roohi Mariam Peter

In Depth 16 Nov 2023

Meet the ‘biotech mafia’: how specialized biotech VC firms are dominating industry funding once again

Between 2020 and 2022 – largely due to the biotech innovations that came about by the COVID-19 pandemic – there was an influx of generalist investors in the biotech industry, betting big on new technologies like mRNA vaccines. But, now, these investors appear to have backed off, leaving room for specialized biotech venture capital (VC) […]

November 16, 2023 - 6 minutesmins - By Willow Shah-Neville

In Depth 15 Nov 2023

Beyond oil and gas: Biotech’s significant place in the Qatar Investment Authority’s strategy

Since 2020, the Qatar Investment Authority (QIA) has been taking part in important biotech fundings reaching its peak in 2021 and remaining strong in 2023. They recently led a $250 million round in the company BridgeBio specialized in transformative medicine for patients suffering from cancer or genetic diseases. This investment is not an isolated case […]

November 15, 2023 - 8 minutesmins - By Jules Adam

Best in Biotech 14 Nov 2023

10 biotech companies leading innovation in the Asia-Pacific region

Asia-Pacific is now establishing itself as a global innovation hub, with China, Japan, and Korea leading the space in overall innovative pipeline assets in the region. The life sciences industry is thriving, and there has been a shift in the region from predominantly producing generics to developing innovative technologies, with several Asia-Pacific biotech companies leading […]

November 14, 2023 - 11 minutesmins - By Willow Shah-Neville

Weekly Roundup 10 Nov 2023

Korro Bio and Frequency’s merger; Lexeo’s $100 million IPO; Gate Biosciences new class of drugs

You are reading Labiotech’s weekly roundup of the latest biotech news. Korro Bio and Frequency Therapeutics close merger Last Friday, Korro Bio announced the completion of the previously announced business combination between Frequency Therapeutics, Inc. and the entity formerly known as Korro Bio. The combined company will now operate under the name Korro Bio, Inc. […]

November 10, 2023 - 12 minutesmins - By Willow Shah-Neville

Shutterstock 657615100 heart surgery repair

Podcast 10 Nov 2023

How biotech can mend a broken heart

CellProthera has been working to do the impossible – mend broken hearts. The biotech company’s ProtheraCytes cell therapy regenerates damaged tissue following a heart attack, thus restoring cardiac function. In this podcast, we investigate regenerative therapy with CellProthera’s CEO, Matthieu de Kalbermatten. While regenerative cell therapy is dependent on the patient’s own cells, and reliant […]

November 10, 2023

In Depth 9 Nov 2023

Blood tests for Alzheimer’s: a hit or a miss?

Doctor’s typically diagnose Alzheimer’s with the help of brain imaging and cognitive tests, along with taking a patient’s medical history into account. But lately, blood tests are gaining recognition for its ability to rule out other potential causes of memory loss, and to diagnose Alzheimer’s more quickly. With American healthcare company Labcorp launching its trio […]

November 9, 2023 - 10 minutesmins - By Roohi Mariam Peter

Best in Biotech 7 Nov 2023

Eight biotech companies tackling infectious diseases head-on

Infectious diseases are diseases that are caused by pathogens that enter the body, hijack the body’s immune system and multiply, causing an infection. Five of the deadliest infectious diseases are measles, tuberculosis, malaria, diarrhoeal disease and influenza, according to the World Economic Forum. While Our World in Data statistics suggest that there has been almost […]

November 7, 2023 - 11 minutesmins - By Roohi Mariam Peter

In Depth 6 Nov 2023

The biggest private biotech investments in October 2023

The companies Aiolos Bio, MapLight Therapeutics and Agomab Therapeutics bagged the biggest biotech investments in October 2023. Around the world, biomaterials, central nervous system and musculoskeletal disorder players attracted the most investor interest. October 2023 saw a lot of fundraising taking place both in and out of healthcare in the U.S. and Europe. However, the […]

November 6, 2023 - 3 minutesmins - By Willow Shah-Neville

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

M&As: what’s up with the ADC buying spree?

With $700 million Q3 rise, U.K. biotech spearheads European recovery

How can life-saving vaccines be more affordable?

uniQure: is the gene therapy pioneer en route to becoming a biotech rebuff?

Meet the ‘biotech mafia’: how specialized biotech VC firms are dominating industry funding once again

Beyond oil and gas: Biotech’s significant place in the Qatar Investment Authority’s strategy

10 biotech companies leading innovation in the Asia-Pacific region

Korro Bio and Frequency’s merger; Lexeo’s $100 million IPO; Gate Biosciences new class of drugs

How biotech can mend a broken heart

Blood tests for Alzheimer’s: a hit or a miss?

Eight biotech companies tackling infectious diseases head-on

The biggest private biotech investments in October 2023

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!